---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-039394"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2023-11-17T23:59:59+00:00"
generated_at: "2026-06-08T00:03:38.491048+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience reports FY2023 revenue $245.1M (+20% YoY), net loss $3.60/sh; FY2024 guide $285-290M

## Summary
- FY2023 revenue $245.1M, up 20% from $203.6M; orders $264M, up 17% from $226.4M.
- FY2023 net loss attributable to common stockholders $204.6M ($3.60 per share), down from $217.9M ($4.04) prior year.
- Q4 revenue $66.9M, up 17% YoY from $57.3M; Q4 net loss $46.2M ($0.81 per share).
- Guidance: FY2024 revenue expected $285M-$290M, reflecting growth.
- Recent highlights: signed Bayer antibody deal worth up to $188M milestones; launched Twist Express Genes with 5-7 day turnaround.

## SEC filing metadata
- accession: 0001628280-23-039394
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2023-11-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000162828023039394/0001628280-23-039394-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000162828023039394/twist-20231117.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-039394
- JSON: https://secwatch.observer/filing/0001628280-23-039394.json
- Plain text: https://secwatch.observer/filing/0001628280-23-039394.txt

## Key facts
- Earnings Releases
  Twist Bioscience Corp reported Fiscal year ended September 30, 2023 results: revenue $245.1 million, net income -$204.6 million, EPS -$3.60 per share.
  - Period: Fiscal year ended September 30, 2023
  - Revenue: $245.1 million
  - Net income: -$204.6 million
  - EPS: -$3.60 per share
  - Result: reported results
  source text: FISCAL 2023 FINANCIAL RESULTS • Orders : Total orders received for fiscal 2023 grew to $264 million compared to $226.4 million for fiscal 2022. • Revenue : Total revenues for fiscal 2023 grew to $245.1 million compared to $203.6 million for fiscal 2022. • Cost of Revenues : Cost of revenues for fiscal 2023 grew to $155.4 million compared to $119.3 million for fiscal 2022. • Research and Development Expenses : Research and development expenses for fiscal 2023 decreased to $106.9 million compared to $120.3 million for fiscal 2022. • Selling, General and Administrative Expenses: Selling, general and administrative expenses for fiscal 2023 decreased to $189.7 million compared to $212.9 million for fiscal 2022. • Net Loss: Net loss attributable to common stockholders for fiscal 2023 decreased to $204.6 million , or $3.60 per share, compared to $217.9 million , or $4.04 per share, for fiscal 2022. • Cash Position: As of September 30, 2023 , the company had $336.4 million in cash, cash equiva
  evidence_url: https://www.sec.gov/Archives/edgar/data/1581280/000162828023039394/0001628280-23-039394-index.htm
- Earnings Releases
  Twist Bioscience Corp reported Full year Fiscal 2024 results: revenue $285 million to $290 million. Guidance initiated.
  - Period: Full year Fiscal 2024
  - Revenue: $285 million to $290 million
  - Guidance: initiated
  - Result: guidance update
  source text: — Expect revenue in the range of $285 million to $290 million for full year Fiscal 2024 --
  evidence_url: https://www.sec.gov/Archives/edgar/data/1581280/000162828023039394/0001628280-23-039394-index.htm
- Earnings Releases
  Twist Bioscience Corp reported Three months ended September 30, 2023 results: revenue $66.9 million, net income -$46.2 million, EPS -$0.81 per share.
  - Period: Three months ended September 30, 2023
  - Revenue: $66.9 million
  - Net income: -$46.2 million
  - EPS: -$0.81 per share
  - Result: reported results
  source text: FISCAL 2023 FOURTH QUARTER FINANCIAL RESULTS • Orders: Total orders received for the fourth quarter of fiscal 2023 grew to $71.1 million compared to $62.1 million for the same period of fiscal 2022 . • Revenue: Total revenues for the fourth quarter of fiscal 2023 grew to $66.9 million compared to $57.3 million for the same period of fiscal 2022 . • Cost of Revenues: Cost of revenues for the fourth quarter of fiscal 2023 increased to $42.4 million compared to $31.6 million for the same period of fiscal 2022 . • Research and Development Expenses: Research and development expenses for the fourth quarter of fiscal 2023 decreased to $23.7 million compared to $29.6 million for the same period of fiscal 2022 . • Selling, General and Administrative Expenses: Selling, general and administrative expenses for the fourth quarter of fiscal 2023 decreased to $47.4 million compared to $54.2 million for the same period of fiscal 2022 . • Net Loss: Net loss attributable to common stockholders for the f
  evidence_url: https://www.sec.gov/Archives/edgar/data/1581280/000162828023039394/0001628280-23-039394-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.